APLS241018P25000
- 0.20
- -0.12-37.50%
Apellis Pharmaceuticals Newsroom
Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Apellis Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
Evaluating Market Dynamics and Physician Preferences: Hold Rating on Apellis Pharmaceuticals Amid Syfovre and Izervay Competition
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $39 to $85
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Apellis Pharmaceuticals Analyst Ratings
Buy Rating on Apellis Pharmaceuticals Anchored in Syfovre's Market Share Potential Despite EU Setback
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $39
Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities
Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan
Apellis Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
Apellis Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $64